Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Merus N.V. (Nasdaq: MRUS), a biotechnology company specializing in innovative multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The company's President and CEO, Bill Lundberg, M.D., will engage in a fireside chat on Tuesday, April 8, 2025, at 8:45 a.m. ET. Investors and interested parties can access the live webcast through the Investors section of the Merus website, where the presentation recording will remain available for a time following the event.
Details
News Market Reaction – MRUS
The recorded move for MRUS in the trading session of this news was -5.92%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025 at 8:45 a.m. ET.
The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event.
About Merus
Merus is an oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and LinkedIn.
Multiclonics®, Biclonics®, Triclonics® and ADClonics® are registered trademarks of Merus N.V.

Investor and Media Inquiries: Sherri Spear Merus N.V. SVP Investor Relations and Strategic Communications 617-821-3246 s.spear@merus.nl Kathleen Farren Merus N.V. IR/Corp Comms 617-230-4165 k.farren@merus.nl
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.